Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Mining the adenovirus virome for oncolytics against multiple solid tumor types

Cancer Gene Therapy volume 18, pages 744–750 (2011)Cite this article

Subjects

Abstract

Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of cancer. Unfortunately, Ad5 is one of the most seroprevalent serotypes, meaning that this virus has to confront additional immunological barriers to be effective in Ad5-immune patients. In this work, we compare Ad5 to 13 other adenoviral serotypes from species B, C, D and E for oncolytic potential in both immunodeficient mouse and immunocompetent hamster models. Our results indicate that species D Ads are not effective oncolytics against most solid tumors. Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. This work strongly supports the consideration of Ad6-based oncolytic therapies for the treatment of breast, ovarian, kidney and liver tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Davison AJ, Benko M, Harrach B . Genetic content and evolution of adenoviruses. J Gen Virol 2003; 84 (Pt 11): 2895–2908.

    Article  CAS  PubMed  Google Scholar 

  2. Pereira HG, Kelly B . Dose-response curves of toxic and infective actions of adenovirus in HeLa cell cultures. J Gen Microbiol 1957; 17: 517–524.

    Article  CAS  PubMed  Google Scholar 

  3. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB . Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211–1218.

    Article  CAS  PubMed  Google Scholar 

  4. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW . Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998; 101: 1013–1019.

    Article  CAS  PubMed  Google Scholar 

  5. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654–4663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT . Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839–6846.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706–9713.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003; 7: 163–173.

    Article  CAS  PubMed  Google Scholar 

  9. Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O . Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J Invest Dermatol 2008; 128: 988–998.

    Article  CAS  PubMed  Google Scholar 

  10. Hoffmann D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O . Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 2007; 18: 51–62.

    Article  CAS  PubMed  Google Scholar 

  11. Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 2009; 69: 5115–5125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Shashkova EV, May SM, Barry MA . Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 2009; 394: 311–320.

    Article  CAS  PubMed  Google Scholar 

  13. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA . Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 2010; 21: 179–190.

    Article  CAS  PubMed  Google Scholar 

  14. Arnberg N . Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009; 19: 165–178.

    Article  CAS  PubMed  Google Scholar 

  15. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96–104.

    Article  PubMed  Google Scholar 

  16. Arnberg N, Edlund K, Kidd AH, Wadell G . Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000; 74: 42–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N . Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 2004; 78: 7727–7736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–319.

    Article  CAS  PubMed  Google Scholar 

  19. Shashkova EV, Spencer JF, Wold WS, Doronin K . Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007; 15: 598–607.

    Article  CAS  PubMed  Google Scholar 

  20. Thomas MA, Spencer JF, Wold WS . Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169–183.

    CAS  PubMed  Google Scholar 

  21. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009; 16: 644–654.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009; 16: 625–637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Weaver EA, Turner MA, Khare R, Borowski W, Barry MA . Characterization of human species C adenovirus serotype 6. Virology 2011; 412: 19–27.

    Article  CAS  PubMed  Google Scholar 

  24. Khare R, May SM, Vetrini F, Ng P, Weaver EA, Barry MA . Increased liver gene therapy by a Kupffer cell-evading adenovirus vector. Mol Ther 2011; 19: 1254–1262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Mary Barry for helpful technical assistance. This work was supported by a grant to MAB from NIH (R01-CA136945) and by the Mayo Clinic Breast Cancer SPORE (P50-CA116201).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

    C Y Chen, E A Weaver, S M May & M A Barry

  2. Division of Infectious Diseases, Translational Immunovirology Program, Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN, USA

    R Khare

  3. Department of Immunology, Mayo Clinic, Rochester, MN, USA

    M A Barry

  4. Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA

    M A Barry

Authors
  1. C Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E A Weaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Khare
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S M May
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M A Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Barry.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

The authors assert that the material presented in this research article is original, has not been previously published, and has not been submitted for publication elsewhere.

Supplementary Information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, C., Weaver, E., Khare, R. et al. Mining the adenovirus virome for oncolytics against multiple solid tumor types. Cancer Gene Ther 18, 744–750 (2011). https://doi.org/10.1038/cgt.2011.47

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.47

Keywords

This article is cited by

Search

Advanced search

Quick links